



Contacts: **Investors:**
Meg McGilley
Chief Financial Officer
(858) 480-0402

Rob Whetstone
Pondel Wilkinson, Inc.
(310) 279-5963

Media:
Anne de Schweinitz
Manning, Selvage & Lee
(212) 468-3779

**SOMAXON PHARMACEUTICALS ANNOUNCES DATA TO BE PRESENTED
AT AMERICAN PSYCHIATRIC ASSOCIATION 161ST ANNUAL MEETING**

Researchers to present data from three Phase 3 clinical trials of
doxepin for the treatment of insomnia

SAN DIEGO, CA – May 2, 2008 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that four posters including data from three Phase 3 clinical trials of the company's product candidate, doxepin for the treatment of insomnia, will be presented at the American Psychiatric Association (APA) 161st annual meeting in Washington, DC on Wednesday, May 7, 2008 from 12pm to 2pm ET. Data from these posters is embargoed until they are presented.

Somaxon Pharmaceuticals' APA 2008 Presentations

- ***APA Poster Presentation # NR6-084; Efficacy of Doxepin 3 and 6 mg on Early Morning Awakenings in Adults with Primary Insomnia:*** A presentation of the effects of 3 mg and 6 mg of doxepin vs. placebo on early morning awakening and next-day residual effects measures in a 35-day Phase 3 clinical trial of doxepin in adults.
- ***APA Poster Presentation # NR6-083; Evaluation of Doxepin 3 and 6 mg in a 35-day Trial of Adults with Primary Insomnia Following Treatment Discontinuation:*** A presentation

evaluating doxepin 3 mg and 6 mg following treatment discontinuation in a 35-day Phase 3 clinical trial of doxepin in adults.

- ***APA Poster Presentation # NR6-090; Long-term Efficacy and Safety of Doxepin 1 and 3 mg in Elderly Subjects with Chronic Primary Insomnia:*** A presentation of the results from a three-month Phase 3 clinical trial exploring the efficacy and safety of doxepin in elderly subjects with chronic primary insomnia.
- ***APA Poster Presentation # NR6-091; Efficacy and Safety of Doxepin 6 mg in a 4-week Outpatient Trial of Elderly Subjects with Primary Insomnia:*** A presentation of the results from a four-week Phase 3 outpatient clinical trial exploring the efficacy and safety of doxepin in elderly subjects with chronic primary insomnia.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. The FDA recently notified Somaxon that it accepted the NDA for SILENOR™ for review as of March 31, 2008. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Somaxon expects that the FDA will complete its review and provide an action letter to the company with respect to the NDA by December 1, 2008.

For more information, please visit the company's web site at www.somaxon.com.

###